医学
观察研究
阿帕奇II
内科学
前瞻性队列研究
重症监护室
作者
Xinyan Liu,Qizhi Wang,Daqiang Yang,Maoliang Fu,Maopeng Yang,Yang Bi,Chunting Wang,Xuan Song
标识
DOI:10.1016/j.clnu.2023.03.004
摘要
ObjectivesRecently, the Gastrointestinal Dysfunction Score (GIDS) was developed for use with critically ill patients. This study evaluated the association of GIDS with disease severity and clinical outcomes to assess the technical feasibility of using GIDS to reflect the severity and short-term prognosis of critically ill patients.MethodsAssociation between Gastrointestinal Dysfunction Score (GIDS) and disease severity and prognosis in critically ill patients: A prospective, observational study.This was a prospective observational study involving adult patients in two Intensive Care Units (ICUs). During the first seven days of ICU admission, GIDS, acute gastrointestinal injury (AGI), Acute Physiology and Chronic Health Evaluation II (APACHE II), and Sequential Organ Failure Assessment (SOFA) scores were assessed daily.ResultsA total of 276 patients from two centers were enrolled in this study. Patients were divided into GIDS 0–1 (121, 43.8%) and GIDS 2–4 (155, 56.2%). The ICU length of stay and 28-day mortality in the GIDS 2–4 group were significantly higher than the GIDS 0–1 group (P = 0.032, P = 0.001, respectively). The APACHE II and SOFA scores in the GIDS 2–4 group were also significantly higher (P < 0.001). The ROC curves of GIDS, AGI, APACHE II, and SOFA scores on the first day of ICU admission for the prediction of 28-day mortality showed that the AUC of GIDS was 0.702 (95%CI 0.628, 0.775; P < 0.001). The AUC for GIDS + SOFA was 0.719 (95%CI 0.648, 0.790; P < 0.001), compared with SOFA alone (AUC = 0.703), showing improved predictive power for 28-day mortality.ConclusionsGIDS represents a step toward a reliable clinical tool for GI dysfunction to assess disease severity and short-term prognosis in critically ill patients. In addition, combining GIDS with SOFA score may better predict mortality risk compared to SOFA score alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI